Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab in EGFR or MET-amplified esophagogastric cancer
NCT05117931Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2021
- Primary completion
- Nov 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of amivantamab in Esophagogastric Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2021; status: active, not recruiting.
02
Drugs
amivantamab
03
Conditions
Esophagogastric Cancer
Beyond the preview
Go deeper on NCT05117931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117931.